See more : Hollywood Intermediate, Inc. (HYWI) Income Statement Analysis – Financial Results
Complete financial analysis of Alpine Immune Sciences, Inc. (ALPN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpine Immune Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- HORNBACH Holding AG & Co. KGaA (HBH.DE) Income Statement Analysis – Financial Results
- Bitdeer Technologies Group (BTDR) Income Statement Analysis – Financial Results
- Nikki Co., Ltd. (6042.T) Income Statement Analysis – Financial Results
- IGIS Value Plus REIT Co., Ltd. (334890.KS) Income Statement Analysis – Financial Results
- The Honest Company, Inc. (HNST) Income Statement Analysis – Financial Results
Alpine Immune Sciences, Inc. (ALPN)
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.88M | 30.06M | 23.44M | 9.34M | 1.74M | 705.00K | 1.73M | 2.95M | 492.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 80.90M | 597.00K | 620.00K | 27.19M | 35.85M | 28.97M | 10.63M | 143.00K | 66.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.03M | 29.47M | 22.82M | -17.85M | -34.11M | -28.27M | -8.90M | 2.81M | 426.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -37.41% | 98.01% | 97.36% | -191.22% | -1,960.17% | -4,009.22% | -513.86% | 95.15% | 86.59% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.90M | 70.24M | 58.74M | 27.19M | 35.85M | 28.97M | 10.63M | 23.32M | 16.05M | 12.20M | 13.14M | 7.10M |
| General & Administrative | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Other Expenses | 0.00 | -97.00K | -4.00K | 1.33M | 812.00K | 1.20M | 0.00 | 0.00 | 80.00K | 296.34K | 0.00 | 150.94K |
| Operating Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Cost & Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Interest Income | 11.85M | 3.29M | 259.00K | 245.00K | 1.25M | 1.30M | 542.00K | 439.00K | 80.00K | 0.00 | 10.00K | 0.00 |
| Interest Expense | 98.00K | 476.00K | 816.00K | 775.00K | 338.00K | 319.00K | 152.00K | 0.00 | 0.00 | 845.10K | 931.00K | 694.07K |
| Depreciation & Amortization | 576.00K | 3.19M | 255.00K | 1.58M | 2.06M | 388.00K | 241.00K | 143.00K | 66.00K | 86.44K | 219.00K | 212.03K |
| EBITDA | -43.67M | -54.96M | -49.60M | -27.17M | -41.51M | -35.33M | -14.19M | -31.90M | -22.90M | -14.10M | -15.05M | -8.67M |
| EBITDA Ratio | -74.18% | -182.80% | -211.59% | -291.07% | -2,385.86% | -5,011.49% | -819.82% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Operating Income | -44.25M | -58.15M | -49.86M | -28.75M | -43.57M | -37.83M | -14.97M | -31.90M | -22.90M | -14.49M | -15.28M | -9.03M |
| Operating Income Ratio | -75.16% | -193.41% | -212.68% | -307.97% | -2,504.25% | -5,365.96% | -865.05% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.17M | 2.72M | -561.00K | 803.00K | 1.72M | 977.00K | 6.99M | 439.00K | 80.00K | -548.76K | -921.00K | -543.14K |
| Income Before Tax | -32.08M | -55.43M | -50.42M | -27.95M | -41.85M | -36.85M | -7.98M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Income Before Tax Ratio | -54.49% | -184.38% | -215.07% | -299.37% | -2,405.29% | -5,227.38% | -461.18% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 103.00K | 2.33M | -87.00K | -6.00K | 682.00K | -366.00K | -200.00K | -143.00K | -66.00K | 1.14M | 941.00K | 845.01K |
| Net Income | -32.18M | -57.76M | -50.33M | -27.94M | -42.53M | -36.49M | -7.78M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Net Income Ratio | -54.66% | -192.13% | -214.70% | -299.30% | -2,444.48% | -5,175.46% | -449.62% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| EPS Diluted | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| Weighted Avg Shares Out | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed.
Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln
Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the companies said on Wednesday.
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late...
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
BOSTON & SEATTLE--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex...
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
BOSTON & SEATTLE--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex...
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
Alpine Immune Sciences (ALPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus...
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual...
Source: https://incomestatements.info
Category: Stock Reports